[1] Alzheimer's Association. 2019 Alzheimer's disease facts and figures includes a special report on Alzheimer's detection in the primary care setting:Connecting patients and physicians[J]. Alzheimer's & Dementia, 2019, 15(3):321-387.
[2] Corder E H, Saunders A M, Strittmatter W J, et al. Gene dose of apolipoprotein-E Type-4 Allele and the risk of Alzheimers-disease in late-onset families[J]. Science, 1993, 261(5123):921-923.
[3] Caselli R J, Dueck A C, Osborne D, et al. Longitudinal modeling of age-related memory decline and the ApoE epsilon4 effect[J]. The New England Journal of Medicine, 2009, 361(3):255-263.
[4] Caselli R J, Dueck A C, Locke D E C, et al. Longitudinal modeling of frontal cognition in ApoE Ε4 homozygotes, heterozygotes, and noncarriers[J]. Neurology, 2011, 76(16):1383-1388.
[5] Yamazaki Y, Zhao N, Caulfield T R, et al. Apolipoprotein E and Alzheimer disease:Pathobiology and targeting strategies[J]. Nature Reviews:Neurology, 2019, 15(9):501-518.
[6] Mahley R W, Huang Y. Apolipoprotein e Sets the stage:Response to injury triggers neuropathology[J]. Neuron, 2012, 76(5):871-885.
[7] Shinohara M, Kanekiyo T, Yang L, et al. ApoE2 eases cognitive decline during aging:Clinical and preclinical evaluations[J]. Annals of Neurology, 2016, 79(5):758-774.
[8] Zhao L, Gottesdiener A J, Parmar M, et al. Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer's disease mouse models[J]. Neurobiology of Aging, 2016, 44:159-172.
[9] Reiman E M, Arboleda-Velasquez J F, Quiroz Y T, et al. Exceptionally low likelihood of Alzheimer's dementia in ApoE2 homozygotes from a 5,000-Person Neuropathological Study[J]. Nature Communications, 2020, 11(1):667.
[10] Insel P S, Hansson O, Mattsson-Carlgren N. Association between apolipoprotein E Ε2 vs Ε4, Age, and β-amyloid in adults without cognitive impairment[J]. JAMA Neurology, 2020, 78(2). doi:10.1001/jamaneurol.2020.3780.
[11] Montagne A, Nation D A, Sagare A P, et al. ApoE4 leads to blood-brain barrier dysfunction predicting cognitive decline[J]. Nature, 2020, 581(7806):71-76.
[12] Verghese P B, Castellano J M, Garai K, et al. ApoE influences Amyloid-β (Aβ) clearance despite minimal ApoE/Aβ association in physiological conditions[J]. PNAS, 2013, 110(19):E1807-E1816.
[13] Huang Y, Mahley R W. Apolipoprotein E:Structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases[J]. Neurobiology of Disease, 2014, 72 Pt A:3-12.
[14] Zhao N, Ren Y, Yamazaki Y, et al. Alzheimer's risk factors age, ApoE genotype, and sex drive distinct molecular pathways[J]. Neuron, 2020, 106(5):727-742.e6.
[15] Huang Y W A, Zhou B, Wernig M, et al. ApoE2, ApoE3, and ApoE4 differentially stimulate APP transcription and Aβ secretion[J]. Cell, 2017, 168(3):427-441.e21.
[16] Holtzman D M, Herz J, Bu G. Apolipoprotein E and apolipoprotein E receptors:Normal biology and roles in Alzheimer disease[J]. Cold Spring Harbor perspectives in medicine, 2012, 2(3):a006312.
[17] Kim J, Basak J M, Holtzman D M. The role of apolipoprotein E in Alzheimer's disease[J]. Neuron, 2009, 63(3):287-303.
[18] Cai H, Cong W, Ji S, et al. Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disorders[J]. Current Alzheimer Research, 2012, 9(1):5-17.
[19] Giil L M, Midttun Ø, Refsum H, et al. Kynurenine pathway metabolites in Alzheimer's disease[J]. Journal of Alzheimer's Disease, 2017, 60(2):495-504.
[20] Varma V R, Oommen A M, Varma S, et al. Brain and blood metabolite signatures of pathology and progression in Alzheimer disease:A targeted metabolomics study[J]. PLoS Medicine, 2018, 15(1):e1002482.
[21] Nho K, Kueider-Paisley A, Mahmoudiandehkordi S, et al. Altered bile acid profile in mild cognitive impairment and Alzheimer's disease:Relationship to neuroimaging and CSF biomarkers[J]. Alzheimer's & Dementia?, 2019, 15(2):232-244.
[22] Cunnane S C, Trushina E, Morland C, et al. Brain energy rescue:An emerging therapeutic concept for neurodegenerative disorders of ageing[J]. Nature Reviews Drug Discovery, 2020, 19(9):609-633.
[23] Chang S, Ran Ma T, Miranda R D, et al. Lipid-and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity[J]. PNAS, 2005, 102(51):18694-18699.
[24] Zhao J, Davis M D, Martens Y A, et al. ApoE ε4/ε4 diminishes neurotrophic function of human iPSC-derived astrocytes[J]. Human Molecular Genetics, 2017, 26(14):2690-2700.
[25] Hanson A J, Bayer-Carter J L, Green P S, et al. Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides:Randomized clinical trial[J]. JAMA Neurology, 2013, 70(8):972-980.
[26] Heinsinger N M, Gachechiladze M A, Rebeck G W. Apolipoprotein E genotype affects size of ApoEcomplexes in cerebrospinal fluid[J]. Journal of Neuropathology and Experimental Neurology, 2016, 75(10):918-924.
[27] Yassine H N, Feng Q, Chiang J, et al. ABCA1-mediated cholesterol efflux capacity to cerebrospinal fluid is reduced in patients with mild cognitive impairment and Alzheimer's disease[J]. Journal of the American Heart Association, 2016, 5(2):e002886.
[28] Bandaru V V R, Troncoso J, Wheeler D, et al. ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brain[J]. Neurobiology of Aging, 2009, 30(4):591-599.
[29] Asaro A, Carlo-Spiewok A S, Malik A R, et al. Apolipoprotein E4 disrupts the neuroprotective action of sortilin in neuronal lipid metabolism and endocannabinoid signaling[J]. Alzheimer's & Dementia, 2020, 16(9):1248-1258.
[30] Bazinet R P, Layé S. Polyunsaturated fatty acids and their metabolites in brain function and disease[J]. Nature Reviews:Neuroscience, 2014, 15(12):771-785.
[31] Liu L, Zhang K, Sandoval H, et al. Glial lipid droplets and ROS induced by mitochondrial defects promote neurodegeneration[J]. Cell, 2015, 160(1/2):177-190.
[32] Ioannou M S, Jackson J, Sheu S H, et al. Neuron-astrocyte metabolic coupling protects against activity-induced fatty acid toxicity[J]. Cell, 2019, 177(6):1522-1535.e14.
[33] Liu L, Mackenzie K R, Putluri N, et Al. The glia-neuron lactate shuttle and elevated ROS promote lipid synthesis in neurons and lipid droplet accumulation in glia via ApoE/D[J]. Cell Metabolism, 2017, 26(5):719-737. e6.
[34] Alexander G E, Chen K, Pietrini P, et al. Longitudinal PET evaluation of cerebral metabolic decline in dementia:A potential outcome measure in Alzheimer's disease treatment studies[J]. The American Journal of Psychiatry, 2002, 159(5):738-745.
[35] Minoshima S, Frey K A, Koeppe R A, et al. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET[J]. Journal of Nuclear Medicine?:Official Publication, Society of Nuclear Medicine, 1995, 36(7):1238-1248.
[36] Butterfield D A, Halliwell B. Oxidative stress, dysfunctional glucose metabolism and alzheimer disease[J]. Nature Reviews:Neuroscience, 2019, 20(3):148-160.
[37] Reiman E M, Caselli R J, Yun L S, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the Epsilon 4 allele for apolipoprotein E[J]. The New England Journal of Medicine, 1996, 334(12):752-758.
[38] Reiman E M, Chen K, Alexander G E, et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia[J]. PNAS, 2004, 101(1):284-289.
[39] Small G W, Ercoli L M, Silverman D H, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease[J]. PNAS, 2000, 97(11):6037-6042.
[40] Nielsen H M, Chen K W, Lee W, et al. Peripheral ApoE isoform levels in cognitively normal ApoE Ε3/Ε4 individuals are associated with regional gray matter volume and cerebral glucose metabolism[J]. Alzheimer's Research & Therapy, 2017, 9(1):5.
[41] Wu L, Zhang X, Zhao L. Human ApoE isoforms differentially modulate brain glucose and ketone body metabolism:Implications for Alzheimer's disease risk reduction and early intervention[J]. The Journal of Neuroscience?:The Official Journal of the Society for Neuroscience, 2018, 38(30):6665-6681.
[42] Jagust W J, Landau S M. Apolipoprotein E, not fibrillar β-amyloid, reduces cerebral glucose metabolism in normal aging[J]. The Journal of Neuroscience?:The Official Journal of the Society for Neuroscience, 2012, 32(50):18227-18233.
[43] Reger M A, Henderson S T, Hale C, et al. Effects of β-hydroxybutyrate on cognition in memory-impaired adults[J]. Neurobiology of Aging, 2004, 25(3):311-314.
[44] Henderson S T, Vogel J L, Barr L J, et al. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease:A randomized, double-blind, placebo-controlled, multicenter trial[J]. Nutrition and Metabolism, 2009, 6(1):31.
[45] Claxton A, Baker L D, Wilkinson C W, et al. Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's Disease[J]. Journal of Alzheimer's Disease:JAD, 2013, 35(4):789-797.
[46] Shi Y, Yamada K, Liddelow S A, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy[J]. Nature, 2017, 549(7673):523-527.
[47] Lin Y T, Seo J, Gao F, et al. ApoE4 causes widespread molecular and cellular alterations associated with Alzheimer's disease phenotypes in human iPSC-derived brain cell types[J]. Neuron, 2018, 98(6):1141-1154.e7.
[48] Narayan P, Sienski G, Bonner J M, et al. PICALM rescues endocytic defects caused by the Alzheimer's disease risk factor ApoE4[J]. Cell Reports, 2020, 33(1):108224.
[49] Sun Y, Wu S, Bu G, et al. Glial fibrillary acidic proteinapolipoprotein E (ApoE) transgenic mice:Astrocyte-specific expression and differing biological effects of astrocyte-secreted ApoE3 and ApoE4 lipoproteins[J]. The Journal of Neuroscience?:The Official Journal of the Society for Neuroscience, 1998, 18(9):3261-3272.
[50] Hartman R E, Wozniak D F, Nardi A, et al. Behavioral phenotyping of GFAP-ApoE3 and-ApoE4 transgenic mice:ApoE4 mice show profound working memory impairments in the absence of Alzheimer's-like neuropathology[J]. Experimental Neurology, 2001, 170(2):326-344.
[51] Brecht W J, Harris F M, Chang S, et al. Neuron-specific apolipoprotein E4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice[J]. The Journal of Neuroscience?:The Official Journal of the Society for Neuroscience, 2004, 24(10):2527-2534.
[52] Buttini M, Masliah E, Yu G Q, et al. Cellular source of apolipoprotein E4 determines neuronal susceptibility to excitotoxic injury in transgenic mice[J]. The American Journal of Pathology, 2010, 177(2):563-569.
[53] Jain S, Yoon S Y, Leung L, et al. Cellular source-specific effects of apolipoprotein (Apo) E4 on dendrite arborization and dendritic spine development[J]. PloS One, 2013, 8(3):e59478.
[54] Raber J, Wong D, Buttini M, et al. Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice:Increased susceptibility of females[J]. PNAS, 1998, 95(18):10914-10919.
[55] Knoferle J, Yoon S Y, Walker D, et al. Apolipoprotein E4 produced in GABAergic interneurons causes learning and memory deficits in mice[J]. The Journal of neuroscience:The official journal of the Society for Neuroscience, 2014, 34(42):14069-14078.
[56] Tong L M, Djukic B, Arnold C, et al. Inhibitory interneuron progenitor transplantation restores normal learning and memory in ApoE4 knock-in mice without or with Aβ accumulation[J]. The Journal of neuroscience:The official journal of the Society for Neuroscience, 2014, 34(29):9506-9515.
[57] Tong L M, Fong H, Huang Y. Stem cell therapy for Alzheimer's disease and related disorders:Current status and future perspectives[J]. Experimental & Molecular Medicine, 2015, 47(3):e151
[58] Wang C, Najm R, Xu Q, et al. Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector[N]. Nature Medicine, 2018:1-11.
[59] Tolar M, Keller J N, Chan S, et al. Truncated apolipoprotein E (ApoE) causes increased intracellular calcium and may mediate ApoE neurotoxicity[J]. The Journal of Neuroscience:The Official Journal of the Society for Neuroscience, 1999, 19(16):7100-7110.
[60] Tamboli I Y, Heo D, Rebeck G W. Extracellular proteolysis of apolipoprotein E (ApoE) by secreted serine neuronal protease[J]. PloS One, 2014, 9(3):e93120.
[61] Hoe H S, Harris D C, Rebeck G W. Multiple pathways of apolipoprotein E signaling in primary neurons[J]. Journal of Neurochemistry, 2005, 93(1):145-155.
[62] Hu J, Liu C C, Chen X F, et al. Opposing effects of viral mediated brain expression of apolipoprotein E2(ApoE2) and ApoE4 on ApoE lipidation and Aβ metabolism in ApoE4-targeted replacement mice[J]. Molecular Neurodegeneration, 2015, 10:6.
[63] Hudry E, Dashkoff J, Roe A D, et al. Gene transfer of human ApoE isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain[J]. Science Translational Medicine, 2013, 5(212):212ra161.
[64] Rosenberg J B, Kaplitt M G, De B P, et al. AAVrh.10-mediated ApoE2 central nervous system gene therapy for ApoE4-associated Alzheimer's disease[J]. Human Gene Therapy. Clinical Development, 2018, 29(1):24-47.
[65] Andrews-Zwilling Y, Bien-Ly N, Xu Q, et al. Apolipoprotein E4 causes age-and tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice[J]. Journal of Neuroscience, 2010, 30(41):13707-13717.
[66] Li G, Bien-Ly N, Andrews-Zwilling Y, et al. GABAergic interneuron dysfunction impairs hippocampal neurogenesis in adult apolipoprotein E4 knockin mice[J]. Cell Stem Cell, 2009, 5(6):634-645.
[67] Chen H K, Ji Z S, Dodson S E, et al. Apolipoprotein E4 domain interaction mediates detrimental effects on mitochondria and is a potential therapeutic target for Alzheimer disease[J]. Journal of Biological Chemistry, 2011, 286(7):5215-5221.
[68] Chen H K, Liu Z, Meyer-Franke A, et al. Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons[J]. Journal of Biological Chemistry, 2012, 287(8):5253-5266.
[69] Lanfranco M F, Ng C A, Rebeck G W. ApoE lipidation as a therapeutic target in Alzheimer's disease[J]. International Journal of Molecular Sciences, 2020, 21(17):6336.
[70] Solomon A, Turunen H, Ngandu T, et al. Effect of the apolipoprotein E genotype on cognitive change during a multidomain lifestyle intervention:A subgroup analysis of a randomized clinical trial[J]. JAMA Neurology, 2018, 75(4):462-470.
[71] Tremlett H, Bauer K C, Appel-Cresswell S, et al. The gut microbiome in human neurological disease:A review[J]. Annals of Neurology, 2017, 81(3):369-382.
[72] Westfall S, Lomis N, Kahouli I, et al. Microbiome, probiotics and neurodegenerative diseases:Deciphering the gut brain axis[J]. Cellular and Molecular Life Sciences, 2017, 74(20):3769-3787.
[73] Tran T T T, Corsini S, Kellingray L, et al. ApoE genotype influences the gut microbiome structure and function in humans and mice:Relevance for Alzheimer's disease pathophysiology[J]. FASEB Journal?:Official Publication of the Federation of American Societies for Experimental Biology, 2019, 33(7):8221-8231.
[74] Maldonado W J, Parikh I, Naqib A, et al. Synergistic Effects of ApoE and sex on the gut microbiome of young EFAD transgenic mice[J]. Molecular Neurodegeneration, 2019, 14(1):47.
[75] Habes M, Grothe M J, Tunc B, et al. Disentangling heterogeneity in Alzheimer's disease and related dementias using data-driven methods[J]. Biological Psychiatry, 2020, 88(1):70-82.
[76] Mayeux R, Saunders A M, Shea S, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease[J]. New England Journal of Medicine, 1998, 338(8):506-511.
